Citations

Clear

2966 citation(s) found for "Go, Ronald S".

Performance of the CogState computerized battery in the Mayo Clinic Study on Aging
Mielke, Michelle M. , Hagen, Clinton E., Edwards, Kelly K., Roberts, Rosebud O., Jack, Clifford R. , Petersen, Ronald C. , Machulda, Mary M. , Pankratz, V. Shane , Knopman, David S. , Jack, Clifford R , Mielke, Michelle M

Mayo Clinic

Alzheimer's & Dementia | April 9, 2015 | Volume: 11 | Issue: 11 | Pages: 1367-1376

10.1016/j.jalz.2015.01.008 | PMID 25858683 Get It

AbstractIntroductionThe feasibility and validity of brief computerized cognitive batteries at the population‐level are unknown.MethodsNondemented participants (n = 1660, age 50–97 years) in the Mayo Clinic Study on Aging completed the computerized CogState battery and standard neuropsychological battery. The correlation between tests was examined and comparisons between CogState performance on the personal computer (PC) and iPad (n = 331), and in the clinic vs. at home (n = 194), were assessed.ResultsWe obtained valid data on greater than 97% of participants on each test. Correlations between the CogState and neuropsychological tests ranged from −0.462 to 0.531. Although absolute differences between the PC and iPad were small and participants preferred the iPad, performance on the PC was faster. Participants performed faster on Detection, One Card Learning, and One Back at home compared with the clinic.DiscussionThe computerized CogState battery, especially the iPad, was feasible, acceptable, and valid in the population.
Risk and protective factors for cognitive impairment in persons aged 85 years and older
Roberts, Rosebud O., Cha, Ruth H., Mielke, Michelle M. , Geda, Yonas E. , Petersen, Ronald C. , Cha, Ruth H., Boeve, Bradley F. , Machulda, Mary M. , Knopman, David S. , Mielke, Michelle M , Geda, Yonas E

Mayo Clinic

Neurology | April 9, 2015 | Volume: 84 | Issue: 18 | Pages: 1854-1861

10.1212/wnl.0000000000001537 | PMID 25854867 Get It

The Human Alzheimer Disease Project
Rosenberg, Roger N., Petersen, Ronald C.

Mayo Clinic

JAMA Neurology | April 6, 2015 | Volume: 72 | Issue: 6 | Pages: 626

10.1001/jamaneurol.2015.67 | PMID 25844883 Get It

Hemodynamic and Symptomatic Consequences of Ventricular Pacing*
Vlietstra, Ronald E., Osborn, Michael J., Ilstrup, Duane M., Holmes, David R. , Nishimura, Rick A. , Gersh, Bernard J.

Mayo Clinic

Pacing and Clinical Electrophysiology | April 1, 2015 | Volume: 5 | Issue: 6 | Pages: 903-910

10.1111/j.1540-8159.1982.tb00029.x | PMID 6184693 Get It

NISHIMURA, R.A. et al.: Hemodynamic and symptomatic consequences of ventricular pacing. After implantation of a ventricular demand pacemaker (VVI), occasional patients continue to have dizziness, syncope, or near syncope (“pacemaker syndrome”). To identify patients in whom VVI pacing may have deleterious effects, we compared cuff blood pressure responses to VVI pacing with blood pressure responses to atrioventricsler sequential pacing (DVI) or sinus rhythm in 50 consecutive patients. Patients with intact ventriculoatrial conduction had a much greater decrease in systolic blood pressure with VVI pacing (24 ± 11 mm Hg) than those with ventriculoatrial dissociation (−4 ± 15 mm Hg) (P<0.005). Patients who were in heart failure had a lesser decrease in blood pressure with VVI pacing than did those without failure (P<0.05); 13 of the 14 heart failure patients lacked ventriculoatrial conduction. Ten patients had symptomatic dizziness after VVI pacing; the incidence of symptoms was higher in patients with ventriculoatrial conduction (9 of 23) than in those without ventriculoatrial conduction (1 of 27) (P<0.003). We conclude that the presence of intact ventriculoatrial conduction appears to be a crucial determinent of the hemodynamic response to VVI pacing, and its presence may identify patients who are at risk for “pacemaker syndrome.”
Predicting the risk of mild cognitive impairment in the Mayo Clinic Study of Aging
Roberts, Rosebud O., Mielke, Michelle M. , Jack, Clifford R. , Geda, Yonas E. , Rocca, Walter A. , Petersen, Ronald C. , Pankratz, V. Shane , Knopman, David S. , Jack, Clifford R , Mielke, Michelle M , Geda, Yonas E

Mayo Clinic

Neurology | March 18, 2015 | Volume: 84 | Issue: 14 | Pages: 1433-1442

10.1212/wnl.0000000000001437 | PMID 25788555 Get It

HkRP3 Is a Microtubule-Binding Protein Regulating Lytic Granule Clustering and NK Cell Killing
Ham, Hyoungjun , Huynh, Walter , Schoon, Renee A., Vale, Ronald D. , Billadeau, Daniel D.

Mayo Clinic

The Journal of Immunology | March 11, 2015 | Volume: 194 | Issue: 8 | Pages: 3984-3996

10.4049/jimmunol.1402897 | PMID 25762780 Get It

Abstract NK cells provide host defense by killing viral-infected and cancerous cells through the secretion of preformed lytic granules. Polarization of the lytic granules toward the target cell is dependent on an intact microtubule (MT) network as well as MT motors. We have recently shown that DOCK8, a gene mutated in a primary immunodeficiency syndrome, is involved in NK cell killing in part through its effects on MT organizing center (MTOC) polarization. In this study, we identified Hook-related protein 3 (HkRP3) as a novel DOCK8- and MT-binding protein. We further show that HkRP3 is present in lytic granule fractions and interacts with the dynein motor complex and MTs. Significantly, depletion of HkPR3 impaired NK cell cytotoxicity, which could be attributed to a defect in not only MTOC polarity, but also impaired clustering of lytic granules around the MTOC. Our results demonstrate an important role for HkRP3 in regulating the clustering of lytic granules and MTOC repositioning during the development of NK cell–mediated killing.
Soluble suppression of tumorigenicity 2 (sST2), but not galactin‐3, adds to prognostication in patients with systemic AL amyloidosis independent of NT‐proBNP and troponin T
Dispenzieri, Angela , Saenger, Amy K., Kumar, Shaji , Lacy, Martha Q. , Dingli, David , Leung, Nelson , Zeldenrust, Steven R., Hayman, Suzanne R. , Kapoor, Prashant , Grogan, Martha , Hwa, Yi L. , Russell, Stephen J. , Kyle, Robert A. , Jaffe, Allan S. , Saenger, Amy, Buadi, Francis K. , Zeldenrust, Steven, Hwa, Lisa, Jaffe, Allan, Gertz, Morie A. , Go, Ronald S. , Rajkumar, S. Vincent , Jaffe, Allan S. , Leung, Nelson , Dispenzieri, Angela , Russell, Stephen J , Dingli, David

Mayo Clinic

American Journal of Hematology | March 9, 2015 | Volume: 90 | Issue: 6 | Pages: 524-528

10.1002/ajh.24001 | PMID 25753178 Get It

The use of soluble cardiac biomarkers such as N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) and troponin has revolutionized prognostication for patients with AL amyloidosis. Soluble ST2 (sST2) and galectin‐3 have also been reported to have prognostic value in other cardiac patient populations. We identified 502 patients with AL amyloidosis, who provided a research sample and consent to review their medical records between 1/1/2006‐12/31/2010 within 90 days of their diagnosis. Samples were assayed for sST2 and galectin‐3. Within this AL amyloidosis population, overall survival (OS) was 25.5 months (95% CI 18, 35.7 months). Receiver operating curve analyses were done to detect the best cut‐points for sST2 and galectin‐3 to predict both 1‐ and 5‐year OS. The respective cut points for sST2 were 30 and 29.7 ng/mL, while the median sST2 for the entire population was 31 ng/mL (IQR 19.8, 53.6). The respective cut points for galectin‐3 were 11 and 10.4 ng/mL while the median for the entire population was 16.6 ng/mL (IQR 11.5, 24.0). Although on univariate analysis, both sST2 and galectin‐3 were prognostic, upon multivariate analysis, only sST2 was independent of troponin, NT‐proBNP, serum immunoglobulin free light chain, and blood pressure. Not only did sST2 add to previously reported prognostication systems, but a novel prognostication 5‐point system including sST2 was possible. The addition of sST2 – but not galectin‐3 – to existing prognostication systems for patients with AL amyloidosis strengthens the ability to predict for death. Am. J. Hematol. 90:524–528, 2015. © 2015 Wiley Periodicals, Inc.
Prognostic Value of Vascular Invasion in Well-Differentiated Papillary Thyroid Carcinoma
Wreesmann, Volkert B. , Nixon, Iain J. , Rivera, Michael , Katabi, Nora , Palmer, Frank L., Ganly, Ian , Shaha, Ashok R. , Tuttle, R. Michael , Shah, Jatin P. , Patel, Snehal G. , Ghossein, Ronald

Mayo Clinic

Thyroid® | March 6, 2015 | Volume: 25 | Issue: 5 | Pages: 503-508

10.1089/thy.2015.0052 | PMID 25748079 Get It

Background: Vascular invasion (VI) is an important predictor of distant metastasis and possible radioactive iodine (RAI) benefit in follicular, Hürthle cell, and poorly differentiated thyroid carcinomas, but its role in well-differentiated papillary thyroid cancer (WDTC) remains unclear. Methods: Archived pathological material of all differentiated thyroid carcinoma patients undergoing primary surgical treatment at Memorial Sloan-Kettering Cancer Center between 1986 and 2003 was reviewed by two dedicated thyroid pathologists. Only WDTCs were included in the present study. Standard statistical methods were used to assess the relationship between VI and outcomes of interest, including 10-year disease-specific survival (DSS), regional recurrence-free survival (RRFS), and distant recurrence-free survival (DRFS). Results: VI was present in 47 of 698 WDTC (6.7%). VI was significantly associated with tumor size >4.0 cm, extrathyroidal extension, distant metastasis, and RAI treatment. On univariate analysis, VI was predictive of decreased 10-year DRFS, but not DSS or RRFS. On multivariate analysis, VI was not an independent predictor of DRFS. Univariate survival analysis of 422 RAI-naïve WDTC showed that both size >4 cm and VI were predictors of outcome, but only size remained independently predictive on multivariate analysis. Conclusion: The presence of VI is not an independent predictor of outcome in WDTC.